Cannabis and schizophrenia
Pro Research Analysisby 
Searched over 200M research papers
Cannabis and Schizophrenia: A Complex Relationship
Cannabis Use and Psychosis Risk
Increased Risk of Psychosis
Cannabis use has been consistently associated with an increased risk of developing psychosis and schizophrenia. A meta-analysis of prospective studies found that cannabis use doubles the risk of psychosis, with a pooled odds ratio of 2.1, indicating a significant association that cannot be explained by confounding factors or reverse causality1. This relationship is particularly strong in individuals with a preexisting liability to psychosis, suggesting that cannabis acts as a component cause in the development and prognosis of psychotic disorders1 6.
Gene-Environment Interaction
The interaction between genetic predisposition and cannabis use is crucial in understanding this association. Studies have shown that the risk of developing schizophrenia is higher among cannabis users, especially those who start using at a younger age and consume higher amounts of THC3 9. Genetic studies using Mendelian randomization have further supported the causal relationship between cannabis use and schizophrenia, indicating that genetic variants associated with cannabis use also increase the risk of schizophrenia9.
Cognitive Impairments in Schizophrenia and Cannabis Use
Contradictory Findings on Cognitive Function
The impact of cannabis on cognitive functioning in schizophrenia patients is complex and somewhat contradictory. Some studies suggest that patients with schizophrenia who use cannabis may have superior neuropsychological functioning compared to non-users. This is particularly evident in areas such as visual memory, working memory, and executive functioning2 10. However, other studies have found that cannabis use is associated with worse performance in immediate verbal learning and working memory, with some improvements noted upon cessation of cannabis use5.
Neurocognitive Deficits and Cannabis
Neurocognitive deficits are a central feature of schizophrenia, present from the first episode of psychosis (FEP). Research indicates that heavy cannabis use during the previous year correlates with slower processing speed in FEP patients. Additionally, FEP patients with a family history of psychosis perform better in executive functions compared to those without such a history5. This suggests that the cognitive impact of cannabis may vary depending on individual genetic vulnerability and the timing of cannabis use.
Treatment and Management of Cannabis Use in Schizophrenia
Psychological and Pharmacological Interventions
The treatment of cannabis use disorders (CUD) in patients with schizophrenia spectrum disorders (SSD) remains challenging. Psychological interventions such as motivational interviewing and cognitive behavior therapy (CBT) have shown limited effectiveness when targeting cannabis use specifically. However, these interventions appear more effective when addressing multiple substance use disorders collectively8. Pharmacological treatments have shown promise but lack sufficient randomized controlled trials to establish their efficacy conclusively4 8.
Impact on Brain Morphology
The effect of cannabis on brain morphology in schizophrenia patients is still not well understood. Some evidence suggests that chronic cannabis use may alter brain structures in schizophrenia patients, particularly those who continue using cannabis. However, there is no convincing evidence that these alterations occur before the onset of schizophrenia in first-episode patients7.
Conclusion
The relationship between cannabis use and schizophrenia is multifaceted, involving genetic, neurocognitive, and environmental factors. While cannabis use is associated with an increased risk of developing psychosis and may exacerbate cognitive deficits in schizophrenia, some patients may exhibit better cognitive performance. Treatment strategies for cannabis use in schizophrenia patients require further research to determine the most effective approaches. Understanding the gene-environment interactions and the timing of cannabis use is crucial for developing targeted interventions and public health messages.
Sources and full results
Most relevant research papers on this topic
The environment and schizophrenia: the role of cannabis use.
Cannabis use is a component cause in the development and prognosis of psychosis, likely due to gene-environment interaction mechanisms.
Meta-Analysis
Highly CitedThe impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.
Patients with schizophrenia or first-episode psychosis who have a history of cannabis use show superior neuropsychological functioning compared to nonusing patients.
Meta-Analysis
Rigorous JournalHighly CitedRelationship between cannabis use and schizophrenia
Cannabis use is associated with a higher prevalence of schizophrenia, but the relationship remains complex and unclear whether it is causal or a trigger for pathology in vulnerable individuals.
Systematic ReviewRigorous JournalCannabis and schizophrenia.
There is insufficient evidence to determine which psychological therapy or drug therapy is more effective for reducing cannabis use in people with schizophrenia, and cannabidiol's antipsychotic effect remains inconclusive.
Systematic Review
Very Rigorous JournalCannabis use and cognitive impairment in schizophrenia
Cannabis use in schizophrenia patients is associated with worse verbal learning and working memory performance, but improvements occur when cannabis consumption is stopped.
Systematic ReviewRigorous JournalCannabis consumption and psychosis or schizophrenia development
Cannabis use doubles the risk of developing psychosis in vulnerable individuals, with dose and age of first use playing a role, and gene-environment interactions modulating this association.
Systematic ReviewRigorous JournalCannabis abuse and brain morphology in schizophrenia: a review of the available evidence
Chronic cannabis abuse may alter brain morphology in schizophrenia patients, but its impact on high-risk individuals remains inconclusive.
Systematic ReviewTreatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review.
Cannabis use disorders in schizophrenia spectrum disorder patients require further randomized controlled trials to determine effective treatments.
Systematic ReviewCannabis use and risk of schizophrenia: a Mendelian randomization study
Cannabis use is causally associated with increased risk of schizophrenia, regardless of tobacco exposure or pleiotropic effects.
Meta-AnalysisVery Rigorous JournalHighly CitedThe effects of cannabis use on neurocognition in schizophrenia: A meta-analysis
Cannabis use in schizophrenia patients shows small to medium improvements in cognitive performance compared to those without a history of use.
Meta-AnalysisHighly Cited